St. Mary's County's pretrial supervision program, which is winning accolades for its results in getting criminal defendants to show up for trial and avoid new offenses without incarcerating them. The program that has been held up as a model for other Maryland jurisdictions to follow as the role of cash bail in determining who is freed diminishes.
Under current conditions, medical research is not science. It is deceptive. Even when results are positive they are presented in a misleading way to exaggerate their benefit. We hear that the newest cholesterol drug Repatha cuts down heart attacks by 20 percent, which sounds impressive, but in fact after two years only 15 out of 1,000 people benefit, and no lives are saved in this industry-sponsored study — numbers buried by the study's authors. The drug costs $14,000 a year. This is not
All drugs and some chemicals are tested on animals before humans, but no one is really sure how good mice, dogs and others are in predicting the toxic affects on people so a team from Johns Hopkins University aims to find out
Plavix is a blood thinner that prevents the blood from clotting around stents after surgery, which can reduce the risk of heart attack and stroke in people with heart disease. But the drug only works when a liver enzyme in the body activates it. About 30 percent of people have at least one gene variation that might prevent this activation and make the drug less effective.
The fact that clinical trials found that opioids pose a "very small risk of developing addiction, abuse, or other serious side effects" suggests that clinical trials, as they are currently conducted, may not be able to accurately determine the safety of prescription medications.
Federal approval for a new drug can take a decade or more, but researchers at Johns Hopkins University are studying a way to shave off years for medications meant for serious outbreaks of flu, Ebola or other infectious disease
The $1.1 billion allocated by Congress last week to target Zika will mean more money for states and localities to control and monitor for the mosquito-borne virus and for researchers to development of vaccines and diagnostic tests
Researchers from Johns Hopkins University School of Medicine will join several other academic and industry scientists in developing a new, stem cell based method of assessing treatments for schizophrenia and bipolar disorder
Researchers at the University of Maryland School of Medicine will begin testing a Zika vaccine in humans before the end of the year as part of an aggressive effort to curtail the virus blamed for a devastating birth defect
Federal regulators have approved a cholera vaccine developed by the University of Maryland, providing U.S. travelers with their first protection against the virulent infection common in many poor countries.
With an official link established this week by the U.S. Centers for Disease Control and Prevention between Zika and birth defects, and warmer weather expected to propel the mosquito-borne virus north, the push is intensifying for a drug to prevent or treat infections
Researchers at the Johns Hopkins Bloomberg School of Public Health are growing tiny replicas of the human brain to help the study of neurological diseases in a trend many hope could lead to better treatments and even cures for some of the most debilitating illnesses.
Baltimore biotechnology company Profectus BioSciences is testing a vaccine to guard against the Ebola virus on 39 human subjects, a first step toward administering it more broadly in people at risk of exposure to the deadly pathogen.
Nearly all children will catch the common wintertime respiratory infection known as RSV before they are two, but for decades researchers have been unable to develop an means to prevent it. Now a vaccine is showing promise in early trials at Johns Hopkins University.
Looking back at new developments in health, science, and technology this year, one thing is clear — 2015 was a banner year for medical milestones, scientific breakthroughs and technological advances at local universities and biotech companies.
The drug and device industry now funds six times more clinical trials than the federal government, according to Johns Hopkins University researchers. That means companies with financial interests in the studies now have more control over what doctors and patients learn about new treatments.
The drug, called Atezolizumab, is a form of immunotherapy, a new treatment option for patients with some types of lung cancer, bladder cancer and melanoma. Based on early data from a clinical trial, the treatment, which helps the immune system fight cancer, looks promising for women with metastatic, triple-negative breast cancer.
What could be one of the first treatments to delay or prevent Alzheimer's disease received a big boost from the National Institute on Aging, which is putting up $7.5 million to help fund the next round of trials for the drug being developed by Baltimore start-up AgeneBio and the Johns Hopkins University.
Seniors are most likely to develop life-threatening complications from the flu, but Johns Hopkins researchers say they may have found a way to boost the power of the seasonal influenza vaccine to better protect them.
Middle East Respiratory Syndrome, or MERS, is similar to another deadly coronavirus identified a decade ago called Severe Acute Respiratory Syndrome, giving scientists a jump on the investigation into their origins.
Maryland's hospitals and doctors took in more than $7.6 million in payments for research, speeches and other work from drug and device manufacturers in 2014, according to federal authorities who have been releasing payment data periodically.
The U.S. Army Edgewood Chemical Biological Center and the U.S. Army Medical Research Institute of Infectious Diseases are partnering to help expedite progress in the global fight against Ebola. ECBC is working with USAMRIID on two critical studies –a vaccine study and a biomarker study – that will advance the global fight against Ebola.
Research being published Thursday suggests that an Ebola vaccine being developed by Baltimore company Profectus BioSciences is effective against the strain of the virus that has ravaged West Africa, a milestone the company says is a first in the race to prevent future Ebola outbreaks.
At its growing East Baltimore facility, Emergent BioSolutions has produced a booster shot to go with a leading Ebola vaccine candidate, joining in a competitive race to make a safe and effective tool to stop the spread of an outbreak that continues in West Africa and to prevent future outbreaks.
Thousands of people are to be injected with two experimental Ebola vaccines in trials in West Africa within a couple of weeks, and a Baltimore biotechnology company is launching a human trial of its own candidate in June, as scientists and public health officials work to end the deadly epidemic.
After touring a National Institutes of Health lab where scientists are developing a leading Ebola vaccine candidate, President Barack Obama on Tuesday called on Congress to approve $6 billion for relief efforts in Africa and research in the U.S.